ENHANCE trial
Jump to navigation
Jump to search
Introduction
720 patients with familial hypercholesterolemia mean age 46 years,
80% had previously taken statins. Patients were randomized to
simvastatin 80 mg QD plus ezetimibe 10 mg QD or
simvastatin 80 mg QD plus placebo.
Primary endpoint was mean change in carotid artery intima- media thickness. Study sponsored by manufacturer of Zetia.
Results:
- despite improvements in CRP & LDL cholesterol, the change in mean carotid artery initma-media thickness in the combination group was non significantly greater than that in the simvastatin only group 0.0111 mm vs 0.0058 mm
- similar findings were reported for the femoral artery intima- media thickness
- adverse cardiovascular events occured in 7 patients in the simvastatin only group & 10 in the combination group
- adverse effects (treatment-related) were 30% in the simvastatin only group & 34% in the combination group
More general terms
References
- ↑ Merck/Schering-Plough Pharmaceuticals Enhance study. abstract submitted to 2008 Meeting of the American College of Cardiology New York Times
Kastelein JJP et al for the ENHANCE investigators Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med 2008, 358:1504 PMID: https://www.ncbi.nlm.nih.gov/pubmed/18376000
Brown BG and Taylor AJ Does ENHANCE diminish confidence in lowering LDL or in ezetimibe? N Engl J Med 2008, 358:1431 PMID: https://www.ncbi.nlm.nih.gov/pubmed/18376002
Drazen JM et al Cholesterol lowering and ezemtimibe. N Engl J Med 2008, 358:1507 PMID: https://www.ncbi.nlm.nih.gov/pubmed/18376000 - ↑ Prescriber's Letter 15(4): 2008 What You Should Know About Vytorin and the ENHANCE Study Detail-Document#: http://prescribersletter.com/(5bhgn1a4ni4cyp2tvybwfh55)/pl/ArticleDD.aspx?li=1&st=1&cs=&s=PRL&pt=3&fpt=25&dd=240501&pb=PRL (subscription needed) http://www.prescribersletter.com